- Home
- CAC vs PCRX Comparison
CAC vs PCRX Comparison
Compare CAC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAC
- PCRX
- Stock Information
- Founded
- CAC 1875
- PCRX 2006
- Country
- CAC United States
- PCRX United States
- Employees
- CAC N/A
- PCRX N/A
- Industry
- CAC Major Banks
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CAC Finance
- PCRX Health Care
- Exchange
- CAC Nasdaq
- PCRX Nasdaq
- Market Cap
- CAC 688.3M
- PCRX 1.2B
- IPO Year
- CAC 1997
- PCRX 2011
- Fundamental
- Price
- CAC $40.30
- PCRX $26.50
- Analyst Decision
- CAC Buy
- PCRX Buy
- Analyst Count
- CAC 3
- PCRX 6
- Target Price
- CAC $48.00
- PCRX $30.00
- AVG Volume (30 Days)
- CAC 55.1K
- PCRX 605.6K
- Earning Date
- CAC 10-28-2025
- PCRX 11-05-2025
- Dividend Yield
- CAC 4.17%
- PCRX N/A
- EPS Growth
- CAC 4.80
- PCRX N/A
- EPS
- CAC 3.11
- PCRX N/A
- Revenue
- CAC $197,501,000.00
- PCRX $705,848,000.00
- Revenue This Year
- CAC $42.11
- PCRX $7.36
- Revenue Next Year
- CAC $5.51
- PCRX $10.07
- P/E Ratio
- CAC $12.93
- PCRX N/A
- Revenue Growth
- CAC 21.74
- PCRX 2.25
- 52 Week Low
- CAC $34.53
- PCRX $13.04
- 52 Week High
- CAC $50.07
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- CAC 51.94
- PCRX 55.30
- Support Level
- CAC $39.82
- PCRX $26.22
- Resistance Level
- CAC $40.75
- PCRX $27.50
- Average True Range (ATR)
- CAC 0.80
- PCRX 0.90
- MACD
- CAC -0.05
- PCRX -0.12
- Stochastic Oscillator
- CAC 41.24
- PCRX 37.81
About CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.